Here, the authors show that TP53 loss of function and MUSASHI-2 (MSI2) expression are biomarkers of resistance to PRMT5-targeted therapy in B-cell lymphoma. The gene discussed is PRMT5; the disease is B-cell non-Hodgkin lymphoma.